Inventor · disambiguated record
Christian Hess
Also filed as: HESS CHRISTIAN
9 granted patents·11 pending applications·1 citations·filing 2008–2024
75Inventor score
Top patents by PatentIndex Score
20 records- 0173US11319371B2Anti-CD3 antibodiesNumab Therapeutics AG·Filed 2018·Granted May 3, 2022·1 cites·16 claims
- 0270US2025066482A1Antibodies targeting pdl1 and methods of use thereofNumab Therapeutics AG·Filed 2024·Application pending·0 cites
- 0363US2023242651A1Stable antibody variable domain framework combinationsNumab Therapeutics AG·Filed 2022·Application pending·0 cites
- 0462US2022403028A1Novel anti-cd3 antibodiesNumab Therapeutics AG·Filed 2022·Application pending·0 cites
- 0558US12077588B2Antibodies targeting PDL1 and methods of use thereofNumab Therapeutics AG·Filed 2018·Granted Sep 3, 2024·0 cites·28 claims
- 0656US2025282880A1Antibody variable domains that bind il-4rNumab Therapeutics AG·Filed 2021·Application pending·0 cites
- 0756US2024043547A1Antibody variable domains that bind il-31Numab Therapeutics AG·Filed 2021·Application pending·0 cites
- 0856US2009169807A1Langmuir-blodgett nanostructure monolayersUNIV CALIFORNIA·Filed 2008·Application pending·0 cites
- 0954US2025382363A1Antibody Variable Domains And Antibodies Having Decreased ImmunogenicityNumab Therapeutics AG·Filed 2023·Application pending·0 cites
- 1053US12209133B2Antibodies targeting CD137 and methods of use thereofNumab Therapeutics AG·Filed 2019·Granted Jan 28, 2025·0 cites·25 claims
- 1152US11421035B2Stable antibody variable domain framework combinations and methods of use thereofNumab Therapeutics AG·Filed 2018·Granted Aug 23, 2022·0 cites·28 claims
- 1251US12202911B2Multispecific antibody comprising CD137 binding domain and PDL1 binding domainNumab Therapeutics AG·Filed 2018·Granted Jan 21, 2025·0 cites·3 claims
- 1351US11578133B2Antibodies targeting CD137 and methods of use thereofNumab Therapeutics AG·Filed 2018·Granted Feb 14, 2023·0 cites·15 claims
- 1450US12503505B2Multispecific antibodies having specificity for TNFα and IL-17A, antibodies targeting IL-17A, and methods of use thereofNumab Therapeutics AG·Filed 2020·Granted Dec 23, 2025·0 cites·28 claims
- 1550US2025282879A1Multispecific antibodies having specificity for il-4r and il-31Numab Therapeutics AG·Filed 2021·Application pending·0 cites
- 1650US2024392003A1Multispecific antibodies having specificity for ror1 and cd3Numab Therapeutics AG·Filed 2022·Application pending·0 cites
- 1749US2023203162A1Multispecific antibodyNumab Therapeutics AG·Filed 2021·Application pending·0 cites
- 1846US2022411536A1Multispecific antibodyNumab Therapeutics AG·Filed 2020·Application pending·0 cites
- 1942US12098203B2Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSANumab Therapeutics AG·Filed 2018·Granted Sep 24, 2024·0 cites·25 claims
- 2038US11365240B2Anti-HSA antibodiesNumab Therapeutics AG·Filed 2018·Granted Jun 21, 2022·0 cites·12 claims
Join the waitlist — get patent alerts
Get an alert when Christian Hess files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →